Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5783945 | 0.91 | KDM4E (0.51) | KDM4EALDH1A1HSD17B10MAPTHTT | |
| SCHEMBL2415809 | 0.83 | PTGER4 (0.41) | KDM4EALDH1A1HSD17B10MAPTHTT | |
| SCHEMBL2076159 | 0.80 | ACHE (0.55) | KDM4EALDH1A1HSD17B10MAPTHPGD | |
| SCHEMBL25057053 | 0.79 | KDM4E (0.54) | KDM4EALDH1A1HSD17B10MAPTHTT | |
| SCHEMBL27806392 | 0.78 | KDM4E (0.41) | KDM4EALDH1A1HSD17B10MAPTHTT | |
| SCHEMBL2418016 | 0.78 | ALDH1A1 (0.51) | ALDH1A1MAPTHTTRAB9ASMN1; SMN2 | |
| Sulfamide SCHEMBL2416013 | 0.78 | PTGER4 (0.40) | KDM4EALDH1A1HSD17B10MAPTHTT | |
| SCHEMBL12956699 | 0.77 | KDM4E (0.55) | KDM4EALDH1A1HSD17B10MAPTHPGD | |
| SCHEMBL27393494 | 0.77 | KDM4E (0.57) | KDM4EALDH1A1HSD17B10HPGDACHE | |
| SCHEMBL27546031 | 0.76 | KDM4E (0.50) | KDM4EALDH1A1HSD17B10MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863444-B2 | 4-aminopyrrolopyrimidines as kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-01-04 | — | — | US | disclosed |
| US-6713474-B2 | SERINE-THREONINE AND TYROSINE KINASE INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2004-03-30 | — | — | US | disclosed |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-08-14 | — | — | US | disclosed |
| CN-1335849-A | Pyrrolopyrimidines as protein kinase inhibitors | BASF AG (DE) | 2002-02-13 | — | — | CN | disclosed |
| WO-2001072751-A1 | PYRROLOPYRIMIDINES AS TYROSINE KINASE INHIBITORS | KNOLL GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2001-10-04 | — | — | WO | disclosed |
| EP-1114053-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000017203-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | FLT1, FLT4, TFPI | KDM4E 2504/4885ALDH1A1 1374/4885HSD17B10 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.